2026-23692NoticeWallet

FDA Drafts Study Guides to Help Generic Drugs Prove Equivalence

Published Date: 11/20/2026

Notice

Summary

The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like brand-name ones. If you’re in the drug business, these guides show you exactly what the FDA expects, making the approval process smoother and faster. You’ve got until January 19, 2027, to send your feedback before these guides become final—saving time and possibly money down the road!

Analyzed Economic Effects

5 provisions identified: 5 benefits, 0 costs, 0 mixed.

New draft guidances for specific drugs

FDA posted new draft product-specific guidances that give product-specific recommendations on designing bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). The new drafts apply to products containing Aficamten; Barium sulfate; Berotralstat dihydrochloride; Bumetanide; Delgocitinib; Dihydroergotamine mesylate; Ethinyl estradiol; Norethindrone acetate; Imlunestrant tosylate; Lamotrigine; Nerandomilast; Orforglipron; Paltusotine hydrochloride; Remibrutinib; Sepiapterin; and Zongertinib.

Revised draft guidances for listed drugs

FDA posted revised draft product-specific guidances with recommendations on BE study design for ANDAs for products containing Albuterol sulfate; Azathioprine; Betaxolol hydrochloride; Bupropion hydrochloride; Dextromethorphan hydrobromide; Carbinoxamine maleate; Estrogens, conjugated; Gabapentin enacarbil; Ixazomib citrate; Lanreotide acetate; Lenvatinib mesylate; Naltrexone; Nitroglycerin; Pyridostigmine bromide; and Trifarotene.

60‑day public comment deadline (Jan 19, 2027)

Stakeholders may submit electronic or written comments on these draft guidances and must submit them by January 19, 2027 for FDA to consider them before it begins work on the final versions. Comments submitted to https://www.regulations.gov will be posted publicly unless submitted as written/paper confidential submissions following FDA's instructions.

Guidances are non‑binding; alternatives allowed

FDA states that these draft guidances, when finalized, will represent the Agency's current thinking but do not establish any rights and are not binding. You may use an alternative approach if it satisfies the requirements of the applicable statutes and regulations.

FDA will consider cost comments under EO 14192

FDA will consider comments on costs or cost savings the guidance may generate as it develops final guidances, consistent with Executive Order 14192. Stakeholders can submit cost or cost‑savings information for FDA's consideration.

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Published Date
Comments Due
11/20/2026
1/19/2027

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
Food and Drug Administration
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register